The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
Open accessAbstract
A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This workshop developed a set of priorities and action items including the creation of a standardized MRI protocol for multicenter studies. The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials. The minimum recommended sequences include: (i) parameter-matched precontrast and postcontrast inversion recovery-prepared, isotropic 3D T1-weighted gradient-recalled echo; (ii) axial 2D T2-weighted turbo spin-echo acquired after contrast injection and before postcontrast 3D T1-weighted images to control timing of images after contrast administration; (iii) precontrast, axial 2D T2-weighted fluid-attenuated inversion recovery; and (iv) precontrast, axial 2D, 3-directional diffusion-weighted images. Recommended ranges of sequence parameters are provided for both 1.5 T and 3 T MR systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationOstrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834 · cited 3×
“For example, 3 large phase 3 trials were completed, based on promising phase 3 data, which failed to significantly extend OS.5,6,16 These failures highlight the need to optimize the use of imaging as a surrogate tool to better understand the response to novel therapeutics.”
BackgroundSelf-citationBevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations
Padhani, A. R., Liu, G., Mu-Koh, D., Chenevert, T. L., Thoeny, H. C., Takahara, T., Dzik-Jurasz, A., Ross, B. D., Van Cauteren, M., Collins, D., et al. (2009) · Neoplasia · doi:10.1593/neo.81328 · Cited by 1,989
The Alzheimer's Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.008 · Cited by 1,525
Tumor Detection by Nuclear Magnetic Resonance
Damadian, R. (1971) · Science · doi:10.1126/science.171.3976.1151 · Cited by 1,466
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Sugahara, T., Korogi, Y., Kochi, M., Ikushima, I., Shigematu, Y., Hirai, T., Okuda, T., Liang, L., Ge, Y., Komohara, Y., et al. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199901)9:1<53::aid-jmri7>3.0.co;2-2 · Cited by 1,163
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
Self-citationStupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052 · cited 2×
“For example, 3 large phase 3 trials were completed, based on promising phase 3 data, which failed to significantly extend OS.5,6,16 These failures highlight the need to optimize the use of imaging as a surrogate tool to better understand the response to novel therapeutics.”
BackgroundSelf-citationBevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304121.57857.38 · Cited by 801
Standards of care for treatment of recurrent glioblastoma—are we there yet?
Weller, M., Cloughesy, T., Perry, J. R., & Wick, W. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos273 · Cited by 771
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
Weller, M., van den Bent, M., Hopkins, K., Tonn, J. C., Stupp, R., Falini, A., Cohen-Jonathan-Moyal, E., Frappaz, D., Henriksson, R., Balana, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70011-7 · Cited by 750
Guo, A. C., Cummings, T. J., Dash, R. C., & Provenzale, J. M. (2002) · Radiology · doi:10.1148/radiol.2241010637 · Cited by 688
Chenevert, T. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.24.2029 · Cited by 673
Microvessel density is a prognostic indicator for patients with astroglial brain tumors
Leon, S. P., Folkerth, R. D., & Black, P. M. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960115)77:2<362::aid-cncr20>3.0.co;2-z · Cited by 481
Lamborn, K. R., Yung, W. K. A., Chang, S. M., Wen, P. Y., Cloughesy, T. F., DeAngelis, L. M., Robins, H. I., Lieberman, F. S., Fine, H. A., Fink, K. L., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2007-062 · Cited by 421
Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative
Jack, C. R., Bernstein, M. A., Borowski, B. J., Gunter, J. L., Fox, N. C., Thompson, P. M., Schuff, N., Krueger, G., Killiany, R. J., DeCarli, C. S., et al. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.004 · Cited by 378
MP RAGE: a three-dimensional, T1-weighted, gradient-echo sequence--initial experience in the brain.
Brant-Zawadzki, M., Gillan, G. D., & Nitz, W. R. (1992) · Radiology · doi:10.1148/radiology.182.3.1535892 · Cited by 342
Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity
Ellingson, B. M., Malkin, M. G., Rand, S. D., Connelly, J. M., Quinsey, C., LaViolette, P. S., Bedekar, D. P., & Schmainda, K. M. (2010) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22068 · Cited by 277
Wood, J. R., Green, S. B., & Shapiro, W. R. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.338 · Cited by 274
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry
Leow, A. D., Klunder, A. D., Jack, C. R., Toga, A. W., Dale, A. M., Bernstein, M. A., Britson, P. J., Gunter, J. L., Ward, C. P., Whitwell, J. L., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2005.12.013 · Cited by 214
Ellingson, B. M., Kim, H. J., Woodworth, D. C., Pope, W. B., Cloughesy, J. N., Harris, R. J., Lai, A., Nghiemphu, P. L., & Cloughesy, T. F. (2014) · Radiology · doi:10.1148/radiol.13131305 · Cited by 187
Thiesse, P., Ollivier, L., Di Stefano-Louineau, D., Négrier, S., Savary, J., Pignard, K., Lasset, C., & Escudier, B. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.12.3507 · Cited by 168
Warr, D. G., McKinney, S., & Tannock, I. F. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.9.1040 · Cited by 151
Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D?
Dempsey, M. F., Condon, B. R., & Hadley, D. M. (2005) · PubMed · Cited by 147
Galanis, E., Buckner, J. C., Maurer, M. J., Sykora, R., Castillo, R., Ballman, K. V., & Erickson, B. J. (2006) · Neuro-Oncology · doi:10.1215/15228517-2005-005 · Cited by 139
Magnetic Resonance Imaging Contrast Enhancement of Brain Tumors at 3 Tesla Versus 1.5 Tesla
Nöebauer-Huhmann, I.-M., Ba‐Ssalamah, A., Mlynárik, V., Barth, M., Schöggl, A., Heimberger, K., Matula, C., Fog, A., Kaider, A., & Trattnig, S. (2002) · Investigative Radiology · doi:10.1097/00004424-200203000-00003 · Cited by 115
A comparative study at 3 T of sequence dependence of T2 quantitation in the knee
Pai, A., Li, X., & Majumdar, S. (2008) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2008.02.017 · Cited by 114
Comparison of One-, Two-, and Three-Dimensional Measurements of Childhood Brain Tumors
Warren, K. E., Patronas, N., Aikin, A. A., Albert, P., & Balis, F. M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.18.1401 · Cited by 114
Pérez‐Larraya, J. G., Lahutte, M., Petrirena, G. J., Reyes-Botero, G., González-Aguilar, A., Houillier, C., Guillevin, R., Sanson, M., Hoang‐Xuan, K., & Delattre, J. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos070 · Cited by 106
Nagao, E., Yoshiura, T., Hiwatashi, A., et al. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2343 · Cited by 104
Interobserver variability in the radiological assessment of response to chemotherapy in glioma
Vos, M. J., Uitdehaag, B. M. J., Barkhof, F., Heimans, J. J., Baayen, H., Boogerd, W. J., Castelijns, J. A., Elkhuizen, P. H. M., & Postma, T. J. (2003) · Neurology · doi:10.1212/01.wnl.0000049467.54667.92 · Cited by 103
Wesseling, P., van der Laak, J. A. W. M., Link, M., Teepen, H. L. J. M., & Ruiter, D. J. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90115-0 · Cited by 98
Pros and cons of current brain tumor imaging
Ellingson, B. M., Wen, P. Y., van den Bent, M. J., & Cloughesy, T. F. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou224 · Cited by 76
Bidimensional Measurements in Brain Tumors: Assessment of Interobserver Variability
Provenzale, J. M., Ison, C., & DeLong, D. M. (2009) · American Journal of Roentgenology · doi:10.2214/ajr.09.2615 · Cited by 61
Wen, P. Y., Cloughesy, T. F., Ellingson, B. M., Reardon, D. A., Fine, H. A., Abrey, L. E., Ballman, K. V., Bendszuz, M., Buckner, J. C., Chang, S. M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou226 · Cited by 53
Time-dependency in brain lesion enhancement with gadodiamide injection
Åkeson, P., Nordström, C., & Holtås, S. (1997) · Acta Radiologica · doi:10.1080/02841859709171236 · Cited by 51
Chow, K. L., Gobin, Y. P., Cloughesy, T. F., Sayre, J. W., Villablanca, J. P., & Viñuela, F. (2000) · PubMed Central · Cited by 47
Impact of MRI head placement on glioma response assessment
Reuter, M., Gerstner, E. R., Rapalino, O., Batchelor, T. T., Rosen, B. R., & Fischl, B. R. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1403-8 · Cited by 47
Emerging techniques and technologies in brain tumor imaging
Ellingson, B. M., Bendszus, M., Sorensen, A. G., & Pope, W. B. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou221 · Cited by 46
Impact of imaging measurements on response assessment in glioblastoma clinical trials
Reardon, D. A., Ballman, K., Buckner, J. C., Chang, S. M., & Ellingson, B. M. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou286 · Cited by 41
Wintersperger, B. J., Runge, V. M., Biswas, J., Reiser, M. F., & nberg, S. O. S. (2007) · Investigative Radiology · doi:10.1097/rli.0b013e31803e8b3f · Cited by 38
Cited by
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048
Self-citationArtificial intelligence in cancer imaging: Clinical challenges and applications
Bi, W. L., Hosny, A., Schabath, M. B., Giger, M. L., Birkbak, N. J., Mehrtash, A., Allison, T., Arnaout, O., Abbosh, C., Dunn, I. F., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21552 · Cited by 1,846
Bakas, S., Reyes, M., Jakab, A., Bauer, S., Rempfler, M., Crimi, A., Shinohara, R. T., Berger, C., Ha, S. M., Rozycki, M., et al. (2018) · Apollo - University of Cambridge Repository · doi:10.17863/cam.38755 · Cited by 1,441
Self-citationBakas, S., Reyes, M., Jakab, A., Bauer, S., Rempfler, M., Crimi, A., Shinohara, R. T., Berger, C., Ha, S. M., Rozycki, M., et al. (2018) · arXiv · doi:10.48550/arxiv.1811.02629 · Cited by 1,441
Self-citationCloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0337-7 · Cited by 1,382
Metadata
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-08-06
- Volume
- 17
- Issue
- 9
- Pages
- 1188-98
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W1911361012
- Cited by
- 663
- References
- 49
- FWCI
- 19.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.